0002001011-24-000050.txt : 20240502
0002001011-24-000050.hdr.sgml : 20240502
20240502180717
ACCESSION NUMBER: 0002001011-24-000050
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240430
FILED AS OF DATE: 20240502
DATE AS OF CHANGE: 20240502
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Aryeh Jason
CENTRAL INDEX KEY: 0001376960
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33093
FILM NUMBER: 24910132
MAIL ADDRESS:
STREET 1: 11119 NORTH TORREY PINES ROAD
STREET 2: SUITE 200
CITY: LA JOLLA
STATE: CA
ZIP: 92037
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: LIGAND PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000886163
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 770160744
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3911 SORRENTO VALLEY BLVD
STREET 2: SUITE 110
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-550-7500
MAIL ADDRESS:
STREET 1: 3911 SORRENTO VALLEY BLVD
STREET 2: SUITE 110
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0508
4
2024-04-30
0
0000886163
LIGAND PHARMACEUTICALS INC
LGND
0001376960
Aryeh Jason
555 HERITAGE DRIVE
SUITE 200
JUPITER
FL
33458
1
0
0
0
0
Common Stock
2024-04-30
4
M
0
2406
52.3
A
76828
D
Common Stock
51594
I
Indirect
Common Stock
5025
I
by Trust
Non-Qualified Stock Option (right to buy)
52.3
2024-04-30
4
M
0
2406
0.0
D
2025-04-24
Common Stock
2406
0
D
All securities disclosed in this Form 4 are owned by certain funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates (the "Funds"). Jason Aryeh is the General Partner of JALAA Equities, LP and a partner of JLV Investments, LP. By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, JALAA Equities, LP, JLV Investments, LP and affiliates and Mr. Aryeh may be deemed to be the beneficial owners of the securities beneficially owned by the Funds.
This Option was previously reported as a Grant of 2,754 shares, which vested in full on April 24, 2016, at an exercise price of $89.75 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer.
By: /s/ Andrew Reardon, Attorney-in-Fact For: Jason Aryeh
2024-05-02